CA3206537A1 - Use of neuroactive steroids for treatment of sexual dysfunction - Google Patents

Use of neuroactive steroids for treatment of sexual dysfunction

Info

Publication number
CA3206537A1
CA3206537A1 CA3206537A CA3206537A CA3206537A1 CA 3206537 A1 CA3206537 A1 CA 3206537A1 CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A1 CA3206537 A1 CA 3206537A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
administered
acceptable salt
sexual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206537A
Other languages
English (en)
French (fr)
Inventor
Vijayveer BONTHAPALLY
Ellison SUTHOFF
Handan GUNDUZ-BRUCE
Ryan ARNOLD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CA3206537A1 publication Critical patent/CA3206537A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3206537A 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction Pending CA3206537A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142840P 2021-01-28 2021-01-28
US202163142833P 2021-01-28 2021-01-28
US63/142,840 2021-01-28
US63/142,833 2021-01-28
PCT/US2022/014075 WO2022165017A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
CA3206537A1 true CA3206537A1 (en) 2022-08-04

Family

ID=80787167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206537A Pending CA3206537A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Country Status (9)

Country Link
US (1) US20240122945A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284382A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024507638A (cg-RX-API-DMAC7.html)
KR (1) KR20230136599A (cg-RX-API-DMAC7.html)
AU (1) AU2022214187A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206537A1 (cg-RX-API-DMAC7.html)
IL (1) IL304080A (cg-RX-API-DMAC7.html)
MX (1) MX2023008726A (cg-RX-API-DMAC7.html)
WO (1) WO2022165017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL309922A (en) * 2021-07-28 2024-03-01 Sage Therapeutics Inc Crystalline forms of a neuroactive steroid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
SI3705488T1 (sl) * 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
PH12018501923B1 (en) * 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021010744A (es) * 2019-03-04 2022-01-18 Praxis Prec Medicines Inc Metodos para el tratamiento de la perimenopausia y la menopausia.
US20230210870A1 (en) * 2020-06-08 2023-07-06 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones

Also Published As

Publication number Publication date
JP2026120717A (ja) 2026-07-22
EP4284382A1 (en) 2023-12-06
MX2023008726A (es) 2023-12-14
US20240122945A1 (en) 2024-04-18
JP2024507638A (ja) 2024-02-21
KR20230136599A (ko) 2023-09-26
WO2022165017A1 (en) 2022-08-04
AU2022214187A9 (en) 2024-05-23
IL304080A (en) 2023-08-01
AU2022214187A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
US20240122945A1 (en) Use of neuroactive steroids for treatment of sexual dysfunction
WO2022177718A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
US12409176B2 (en) Methods of treating acute depression
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
CZ99597A3 (en) Use of combination of tricyclic or tetracyclic antidepressant, inhibitor of serotonin recatching or inhibitor of monoaminooxidase with a compound inducing neurotransmitter or with a neurotransmitter precursor for preparing a medicament for treating or prevention of sclerosis multiplex or other demyelinisation states
TW201815385A (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
KR20250004125A (ko) 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
KR20230131927A (ko) 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
EP2642988A1 (en) Method and composition for weight-gain management
US11801256B2 (en) Antidepressant-psilocybin co-treatment to assist psychotherapy
CN111973592A (zh) 治疗肌萎缩侧索硬化和神经病的方法
TWI922961B (zh) 用於治療抑鬱症之組合物及方法
CZ301210B6 (cs) Použití desoxypeganinu k ošetrování klinické deprese
CN116847852A (zh) 神经活性类固醇治疗性功能障碍的用途
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
HK40100385A (en) Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions
MXPA01001178A (es) Metodos y composiciones para tratamiento y la prevencion de ciertos trastornos psiquiatricos y medicos mediante el empleo de la moclobemida.
HK40060077A (en) Domperidone compositions and methods for treating depression
Cole NEW THERAPEUTIC DIRECTIONS: PRESENTATIONS FROM THE MOVEMENT DISORDER SOCIETY'S 13TH INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260203

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260226

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260226

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260226

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260514